Eiko LifesciencesBOM:540204 +0.83%74 ROA % is 5.82% as of Mar. 2026, which is 115% above its 10-year median of 2.71. GuruFocus rates BOM:540204 with a GF Score™ of 74/100 and a GF Value™ of ₹78.66 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 1,613 Chemicals companies, Eiko Lifesciences ranks better than 73.22% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Eiko Lifesciences's annualizedNet Income for the quarter that ended in Mar. 2026 was ₹52.0 Mil.
Eiko Lifesciences's average Total Assets over the quarter that ended in Mar. 2026 was ₹893.7 Mil. Therefore, Eiko Lifesciences's annualized ROA % for the quarter that ended in Mar. 2026 was 5.82%.
The historical rank and industry rank for Eiko Lifesciences's ROA % or its related term are showing as below:
BOM:540204'
s ROA % Range Over the Past 10 Years
Min: -4.39 Med: 2.71 Max: 6.12
Current: 6.12
During the past 13 years, Eiko Lifesciences's highest ROA % was 6.12%. The lowest was -4.39%. And the median was 2.71%.
BOM:540204's ROA % is ranked better than 73.22% of 1613
companies
in the Chemicals industry
Industry Median: 2.9
vs BOM:540204: 6.12
Eiko Lifesciences (BOM:540204) ROA % Explanation
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
Eiko Lifesciences ROA % Related Terms
Eiko Lifesciences ROA % Historical Data
* Premium members only.
The historical data trend for Eiko Lifesciences's ROA % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Specialty Chemicals subindustry, Eiko Lifesciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eiko Lifesciences ROA % vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Eiko Lifesciences's ROA % distribution charts can be found below:
* The bar in red indicates where Eiko Lifesciences's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Eiko Lifesciences (BOM:540204) has a ROA % of 5.82% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Eiko Lifesciences and its competitors. This is 115% above median its historical median of 2.71. According to the industry distribution chart, Eiko Lifesciences ranks #432 out of 1613 companies in the Chemicals industry, placing it in the top 26.8%.
Is Eiko Lifesciences' ROA % too high?
Eiko Lifesciences' current ROA % of 5.82% is 115% above median its 10-year median of 2.71. The Chemicals industry median ROA % is 2.90. Eiko Lifesciences' value of 5.82% is 100.7% above this industry median. Based on the distribution chart, Eiko Lifesciences ranks #432 out of 1613 companies in the Chemicals industry, which is above the industry midpoint. Overall, Eiko Lifesciences has a GF Score™ of 74/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eiko Lifesciences' ROA % compare to LIN and SHW?
According to the Chemicals industry distribution chart, Eiko Lifesciences ranks #432 out of 1613 companies for ROA %. This puts Eiko Lifesciences in the upper half of its industry. The industry median ROA % is 2.90. Eiko Lifesciences' value of 5.82% is 100.7% above this benchmark. While the company's 10-year median is 2.71 vs. the industry median of 2.90, Eiko Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Chemicals company?
The median ROA % among Chemicals companies is 2.90, based on 1,613 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eiko Lifesciences's current ROA % of 5.82% is 100.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Eiko Lifesciences and its competitors. For the Chemicals industry, the median ROA % is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eiko Lifesciences's current ROA % is 5.82%, which is 115% above median its own 10-year median of 2.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eiko Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eiko Lifesciences (BOM:540204) is currently considered Significantly Undervalued. The stock's GF Value™ is ₹78.66, compared to a current price of ₹49.65 — trading 36.9% below its estimated fair value. The current ROA % is 5.82%, which is 115% above median its 10-year median of 2.71 and 100.7% above the Chemicals industry median of 2.90. Eiko Lifesciences' overall GF Score™ is 74/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Eiko Lifesciences (BOM:540204), the current ROA % is 5.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eiko Lifesciences (BOM:540204) Overvalued in 2026?
Based on GuruFocus' analysis, Eiko Lifesciences stock appears to be undervalued.
The current stock price of ₹49.65 is trading 36.9% below its estimated GF Value™ of ₹78.66.
GuruFocus considers Eiko Lifesciences to be Significantly Undervalued.
Key valuation signals for BOM:540204:
ROA %: 5.82% (115% above median its 10-year median of 2.71)
GF Value™: ₹78.66 vs. price of ₹49.65 (36.9% below fair value)
Industry Position: 100.7% above the Chemicals median (#432 of 1613)
No single metric tells the full story. See the BOM:540204 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eiko Lifesciences Ltd is a manufacturer, supplier, and exporter of specialty chemicals, fine chemicals, and pharma intermediates.. The company's segment includes Agrochemicals, Oleo Chemicals, Pharmaceuticals, Food Additives, clinical research, development, and Logistics. Geographically, the company generates the majority of its revenue from the Domestic market.
74GF Score
Get the complete analysis for BOM:540204
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540204 has been successfully added to your 
